Back to results
US 12,742,792 B2Granted
Methods and systems to detect and quantify the amount of LP-X and other abnormal lipoproteins in a biosample using NMR spectroscopy
AssigneeLaboratory Corporation of America Holdings
InventorsJames D. Otvos, Irina Shalaurova, Alan Remaley, Maureen Sampson, Lita Freeman
Life of this patent
Estimating the term…
Abstract
Described herein are methods and systems for the determination of constituents in biosamples by NMR spectroscopy and more specifically for the determination of lipoprotein constituents LP-X, LP-Y, and LP-Z in blood plasma and serum.
Claims19
A method of diagnosing a subject for the presence of LP-X, comprising the steps of:
- acquiring an NMR spectrum of a biosample obtained from the subject, wherein the NMR spectrum includes a zone from 0.75 ppm to 1.0 ppm;
- and
- programmatically determining the presence of at least one of LP-X or LP-Z in the biosample based on the NMR spectrum of the biosample, wherein the determining comprises application of a first deconvolution model that includes lipoproteins that are present in the zone for a typical human sample but excludes LP-X and LP-Z, and application of a second modified deconvolution model that includes lipoproteins that are present in the zone for a typical human sample and further includes LP-X or LP-Z.
A system for screening a subject for the presence of LP-X, comprising:
- an NMR spectrometer for acquiring a measured lipid signal lineshape of an NMR spectrum of a biosample, wherein the NMR spectrum includes a zone from 0.75 ppm to 1.0 ppm;
- a computer program means for storing the measured lineshape of the sample;
- a computer program means for storing reference spectra for each of a plurality of lipoprotein constituents, wherein one or more of the constituents being LP-X, LP-Y, and LP-Z;
- a computer program means for calculating a calculated lineshape based on the derived concentrations of the lipoprotein constituents of the biosample and the reference spectra;
- and
- a computer program means for comparing the measured lipid signal lineshape and the calculated lineshape to determine the degree of correlation between the calculated lineshape and the measured lipid signal lineshape.
3 more elements
A computer program product for determining the concentration of LP-X in patient biosamples, the computer program product comprising:
- a non-transitory computer readable storage medium having computer readable program code embodied in the medium, the computer-readable program code comprising:
- a computer readable program code that obtains NMR signal spectra that includes a zone from 0.75 ppm to 1.0 ppm, wherein the zone comprises an LP-X methyl proton signal at a first region, an LP-Y methyl proton signal at a second region, and an LP-Z methyl proton signal at a third region;
- and
- a computer readable program code that determines the concentration of LP-X in the biosample.
1 more element
Dependencies are inferred from the claim text.